Answers are grounded in this paper and cite their sources.
Retrospective study highlights colectomy-free survival rates and remission in severe ulcerative colitis patients treated with cyclosporin and immunomodulators.
Background: Many patients with severe ulcerative colitis (UC) fail to respond to first-line corticosteroids and require second-line rescue therapy with cyclosporin (CsA) to avoid colectomy. Objectives: To assess the short- and long-term effectiveness and safety of CsA therapy. Design: A single-center, retrospective study was conducted, including patients who received IV CsA therapy for severe, steroid-refractory UC. Methods: Data on therapeutic response and adverse events (AEs) were reported. The Kaplan-Meier method was used to estimate colectomy-free survival rates. The incidence of inflammatory bowel disease flare-ups and the use of advanced therapies after CsA discontinuation were also assessed. Regression analyses were performed to identify predictors for therapeutic response, colectomy, and AEs with CsA. Results: A total of 92 UC patients (54.4% male, mean age: 40.0 ± 14.0 years) were included with the median follow-up time of 14 years (IQR: 7–18). Clinical response was achieved in 88.0%, and clinical remission was observed in 23.9% of patients after the median 6-day (IQR: 7–5) IV phase. A total of 40.7% of responders experienced clinical remission, whereas 13.6% had endoscopic remission at the time of CsA withdrawal (median after 5 months of therapy). Patients receiving concomitant immunomodulators were more likely to achieve clinical remission with CsA ( p = 0.002; OR: 6.4). After CsA discontinuation, 23.5% of patients relapsed within 6 months, while 59.3% of patients were started on biologics. The probability of colectomy-free survival was 74.7%, 62.6%, 57.1%, and 45.6% at 1, 3, 5, and 14 years after CsA initiation. AEs were reported in 53.3% of patients, mainly hyperlipidaemia, hypertension, and infections. Hypoalbuminaemia (<35 g/L) at treatment initiation increased the risk of AEs ( p = 0.03; OR: 0.4), whereas the occurrence of AEs was not associated with concomitant immunomodulator use ( p = 0.9). Conclusion: CsA may be a potent therapeutic option to induce remission in steroid-refractory, severely active UC, and its effectiveness may be enhanced by the concomitant use of immunomodulators, without compromising safety.
No takes yet. Share an insight, caveat, or question.
Farkas et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: